FOR IMMEDIATE RELEASE: February 13, 2024 [San Jose, California 02/13/24] – The Multidisciplinary Association for Psychedelic Studies (MAPS) has announced that the Psychedelic Science 2025 Conference …
FOR IMMEDIATE RELEASE: February 9, 2024 The Multidisciplinary Association for Psychedelic Studies (MAPS) congratulates Lykos Therapeutics, formerly MAPS Public Benefit Corporation, on its announcement …
By Kevin Cranford, Jr. M.S. MAPS Bulletin: Volume XXXIII Number 2 • 2023
By Joseph McCowan, Psy.D. MAPS Bulletin: Volume XXXIII Number 1 • 2023
By Sia Henry, J.D. MAPS Bulletin: Volume XXXIII Number 1 • 2023
FOR IMMEDIATE RELEASE: January 16, 2024 The Multidisciplinary Association for Psychedelic Studies (MAPS) reintroduces itsFiscal Sponsorship Program, signaling a new era of support for grassroots organizations …
FOR IMMEDIATE RELEASE: January 5, 2024 A decade after it was founded as a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation (MAPS …
On December 28, 2023, the FDA Informed MAPS that the Partial Clinical Hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) would be continued. This Clinical Hold letter rejects the …